[
  {
    "ts": null,
    "headline": "Jim Cramer on Johnson & Johnson (JNJ): Tariff-Proof, Drug-Driven, and Still a Buy",
    "summary": "We recently published a list of Jim Cramer Sees Opportunity in Pessimism and Highlights These 12 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer pushed back against […]",
    "url": "https://finnhub.io/api/news?id=7ec6894557c3de33cb7fd591d0866d2898b66fc5008465fac14c22c525545a6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745003332,
      "headline": "Jim Cramer on Johnson & Johnson (JNJ): Tariff-Proof, Drug-Driven, and Still a Buy",
      "id": 133969872,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Sees Opportunity in Pessimism and Highlights These 12 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his latest appearance on CNBC’s Squawk on the Street, Jim Cramer pushed back against […]",
      "url": "https://finnhub.io/api/news?id=7ec6894557c3de33cb7fd591d0866d2898b66fc5008465fac14c22c525545a6e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Pivots Its AI Strategy",
    "summary": "The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.",
    "url": "https://finnhub.io/api/news?id=681d593d6d10bd656321e73b4fb6fde44dbf6a4cf7d750e373f5191a2b7cdb39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744974000,
      "headline": "Johnson & Johnson Pivots Its AI Strategy",
      "id": 133964563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company is making a shift to focus on only the highest-value GenAI use cases and shut down pilots that were redundant or underdelivering.",
      "url": "https://finnhub.io/api/news?id=681d593d6d10bd656321e73b4fb6fde44dbf6a4cf7d750e373f5191a2b7cdb39"
    }
  },
  {
    "ts": null,
    "headline": "How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson Stock",
    "summary": "Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It will report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post EPS of $2.59, down from $2.71 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $21.60 billion, up from $21.38 billion a year earlier. Don't Miss: Deloitte's fastest-growing software company partners with Am",
    "url": "https://finnhub.io/api/news?id=30a4d476abc936455cbf041c48eb52465576523c9ad50fd7f2b9f3a7f7b23484",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744941676,
      "headline": "How To Put $100 In Your Retirement Fund Each Month With Johnson & Johnson Stock",
      "id": 133964564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It will report its Q1 2025 earnings on April 15. Wall Street analysts expect the company to post EPS of $2.59, down from $2.71 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $21.60 billion, up from $21.38 billion a year earlier. Don't Miss: Deloitte's fastest-growing software company partners with Am",
      "url": "https://finnhub.io/api/news?id=30a4d476abc936455cbf041c48eb52465576523c9ad50fd7f2b9f3a7f7b23484"
    }
  }
]